Buddyboy20
3 hours ago
I have been told from, as you put it, "a solid source" the Dr David F Welch was asked about your post. That he read your post, and said it was not true. He has not sold his shares. I guess, like swordman said, we will see when the next SEC filing comes, after the end of the year. Until then, you are just spreading FUD. Which, as I have repeatedly stated, makes you a fool, for bashing your own investment.
fung_derf
4 hours ago
When I see any good news, such as a legitimate individual or institution buying, or us getting within 1-2 years of commercialization, you can bet I will post that.
What about your speech that you were going to leave the boards for your sanity and if NVDA wasn't under $100 by year end you'd leave for good?
How can we ever trust you again?
Blueheel1
Re: Buddyboy20 post# 233691
Sunday, October 27, 2024 11:08:34 AM
Post#
233693
of 233832
the reality is, my posts aren't going to change anything - and i'm tired of being negative here, as it doesn't really help anyone (including me). at the end of the day, it's just money, and i do think there is some chance one of the company's efforts yields some fruit at some point. part of my frustration is wanting a recovery in value in the near term - but it's just not realistic as even Jay has said we're in a re-boot phase.
i'm going to reduce or maybe totally retire from the whole chat board thing and remove the ticker from my phone and computer - it's just a healthier approach i think. and if something happens, it'll be a happy surprise. good luck to you and all longs.
Blueheel1
Re: fung_derf post# 217
Saturday, September 21, 2024 11:09:10 AM
Post#
220
of 247
my short on NVDA isn't a day trade - i will hold for another year or so - as long as it takes. I'll cover at maybe $20 or $25 - even though i think it will eventually bottom at $15 or lower. But i don't want to argue about it - life is too short. you don't have to join, but i stick to my word. In fact, if it's higher than even $100 by year end, i'll delete all of my accounts from every board. I'm sure some people will be thrilled with that :)
Monroe1
4 hours ago
The more than handful of whales are not going anywhere for a long time. Me neither. Too bad for Grip & Sip being 8 months late in his prediction... but he almost made it for yearly December sell off. Yes sir, the PPS will come roaring back once the sellers finish which should not be much longer, then Dr. Jay will release some held back news. Getting ready to add another 10, 000 minimum or so, maybe 50,000 plus as December selling plays out. Only the blind cannot see the turnaround done by Dr. Jay and team and why the team just keeps returning to past strength. Max Lataillade, Dr. Melissa Palmer, Richard Pestell, M.D., Ph.D. all new addtions ready willing and very able.
FDA seems to agree. So as the pigeons cackle and the blind stumble, the real investors recognize the turn around and the real value of leronlimab and the potential that is being realized. Just think where we would be had the FDA not prevented Leronlimab from it's deserved EUA. We have the one MAB that doesn't even cause heartburn while blocking ccr5 and allowing the immune system to function normally plus aiding also in recovery. This mechanism of action is unlike any other...a few of which have been approved to the lucky paid up members of ClubPigPharma. True science will get us there and then everyone will clamor for some. Can the blind not see what the significance of what this means: https://www.natap.org/2024/HIVR4P/HIVR4P_30.htm
And the myriad of data accumulated over the years in studies and now the Cancer trials to begin.
November 4, 2024
CytoDyn Announces FDA Clearance of Its
Phase II Oncology Trial
VANCOUVER, Washington, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:
CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a
CCR5 antagonist with the potential for multiple therapeutic indications, announced today
that it has received clearance from the FDA to commence its Phase II oncology trial. The
study will evaluate the efficacy of leronlimab in patients with relapsed/refractory
microsatellite stable colorectal cancer (“CRC”).
This milestone reflects the continued positive development of the Company’s improved
relationship with the FDA. Clearance for the Phase II oncology trial was achieved following
productive feedback sessions with the FDA over the past few months and the submission of
a final study protocol to the FDA in September 2024. As previously announced, the trial will
be conducted in partnership with Syneos Health. A trial kickoff meeting has been set for late
November 2024 and patient enrollment will begin in early 2025.
“We have appreciated the opportunity to work constructively with the FDA on the review and
finalization of our CRC protocol,” said Dr. Jacob Lalezari CEO. “With the agency’s input and
our partnership with Syneos Health, we are well positioned to advance our clinical evaluation
of leronlimab for oncology and make real strides towards developing the treatment paths of
tomorrow.”
About CytoDyn
CytoDyn is a clinical-stage biotechnology company focused on the development and
commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody
(mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the
surface of certain immune system cells that is believed to play a role in numerous disease
processes. Leronlimab is being studied for oncology and inflammation, as well as other
potential indications, including but not limited to HIV and MASH.
$CYDY$ Good job balancing the warrant release over time... big investors are pleased and ready to add even more. This is what a smart CEO does for his company. So looking forward to what is coming after the Holidays and the new trial enrollment adds the patients. But wait,,, there is more as you will find out. 2025 and I do love my weekends. Happy Friday longs and least we not forget tomorrow, "the date that will live in infamy". December 7, 1941. We have much to be thankful for. God Bless.
fung_derf
2 days ago
I've looked through many different sources and cannot find anywhere where Welch has dumped his shares. He has moved them to protective Trusts, but I can't find out how the heck he is monetizing currently. As far as I can tell, he basically owns most of the voting rights, and has converted a ton of debt to shares, but as far as I can tell, maybe Tanya does her job a bit better than you give her credit for.
Of course, in my opinion, her job does not entail protecting you at all.
P.S....still holding your NVDA short position? Today is 12/4.
theswordman
2 weeks ago
So originally it was not about money but shares he was owed. The sandman got his free millions of shares for acquisition--then cranked his PR folks (gamblermisiurabbitohmmarkschdolphinrockleo etc) and made up a fired for cause case.
Then lied about a prostate test (SEC filed docs show NO test) and would not give the shares that we owed Pestell.
There are several things wrong here. A deal is a deal but as we have seen--nodder will lie and cheat anyone. Ask Samsung,sharp,Patterson,Pestell,Lalezare etc.
#2 When the "for cause" case went to court-- the disgusting coward nodder presented ZERO evidence of cause. ZERO
The delay of years got Pestell penalty/interest of 6 million $$ PLUS ALL the original shares. All shareholders paid. NOT the disgusting coward nodder.
Now you will see the liars scream about wanting Pestell to give his shares back--but NEVER will you see hear ohmrabbitgamblermisiudolphinpersian scream for nodder to give his shares back. GEE--I wonder why??
Since they pretend to want Cydy success and best for shareholders--yet they ONLY want daddy nodder success since he fed free shares for years.
Once AGAIN the liars get caught. Having lied about 13D and Pestell being part of that--and NOW
Having to hide like cowards and claim "banned for life" and "gonna resign mod position" because their lies are exposed. So they can only cower and keep their shares or act like they have some principle and sell and move on because Pestell is back. Support your daddy nodder and sell and move on you phony frauds.
13D was the best hope several years ago. Now years later, millions of $$ later--maybe Dr J Lalezare can save the ship
But make no mistake--the frauds do NOT want Cydy success. Do not want Leronlimab success. Once AGAIN their lies exposed
Kudos Dr Lalezare. Get Dr Patterson back. Get Dr Seethamraju back. Dr Recknor. Mahoob back. People that really want honest RCTs--not kickback fraud. Real progress with FDA--NOT BTD submission using wrong SOC. Not fraud BLA lies for years
Real Drs --not joke kelly, not joke Dr reay. Real partners--not airline bullcrap. Real C R Os
Blueheel1
2 weeks ago
Thanks for sharing. Interesting. As many know, the history with Pestell was pretty nasty - pretty sure he was suing the company at one point and/or vice versa. I have always thought he was an impressive guy however, and chalked much of the controversy up to what a disaster Nader was - and how he drove every qualified person away from the company.
But, I'll beat my dead horse. We don't need new consultants - we need new leadership. I like Jay, and he'd be a great CMO. But let's put a hard core business guy in that seat, and let Jay run the science / trials, which is really what his specialty is. And let's please can the 30 year old lawyer who somehow thinks he's Elon Musk, and please replace Tanya the wealth manager as COB. We can add 20 great consultants - but if the core leadership is weak, it's just window dressing.
How refreshing would it be, to have a new CEO, with a history of turnarounds and deal-making to come in and say "my objective is to maximize shareholder value. Shareholders have suffered far too long, and I'm taking the following specific steps to address that". Oh well, one can dream....
docj
2 weeks ago
CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology
Download as PDFNovember 25, 2024 8:30am EST
VANCOUVER, Washington, Nov. 25, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Richard Pestell, M.D., Ph.D., has been appointed as Lead Consultant, Preclinical and Clinical Oncology. Dr. Pestell will lead the Company’s research and development strategy in oncology and utilize his expertise and vast network to further CytoDyn’s clinical evaluation of the capabilities for leronlimab in cancer treatment.
Dr. Pestell brings over three decades of in-depth research experience to the CytoDyn team, with robust expertise investigating novel drug products and therapies. He is currently the President of the Pennsylvania Cancer and Regenerative Medicine Research Center, a part of the Baruch S. Blumberg Institute in Doylestown, Pennsylvania. Prior to this role, he spent a decade at Thomas Jefferson University in Philadelphia, Pennsylvania, serving as Director of the Sidney Kimmel Cancer Center, Chairman of the Department of Cancer Biology and Executive Vice President. Dr. Pestell’s work has been published in over 600 publications, and his research has been credited with well over 95,000 citations. He previously served as Vice Chairman of the Board, and Chief Medical Officer (CMO), spearheading the Company’s successful effort to obtain Fast Track Designation from the FDA for the use of leronlimab in combination with carboplatin for the treatment of patients with CCR5-positive metastatic triple-negative breast cancer. In addition, Dr. Pestell was instrumental in designing and initiating CytoDyn’s Phase 1b/2 clinical trial in that indication.
“I’m thrilled to welcome Dr. Pestell back to the CytoDyn team. I have known Dr. Pestell personally for a number of years, and I look forward to leveraging his insights and expertise to advance our clinical development pipeline in oncology,” said Dr. Jacob Lalezari, CEO. “As we continue to prioritize the development of leronlimab in oncology, Dr. Pestell’s expertise will help CytoDyn maximize opportunities to pursue breakthrough treatment in a variety of cancer indications.”
Dr. Pestell added, “I am confident that leronlimab holds significant promise for improving patient care and expanding treatment options in oncology. I am eager to support the Company’s efforts to advance our clinical development pipeline and leverage the potential of leronlimab to improve outcomes for cancer patients.”
Dr. Pestell holds a medical degree from the University of Western Australia, and a Ph.D. from the University of Melbourne, Howard Florey Institute. He conducted clinical training in oncology and endocrinology and was inducted as a Fellow of the Royal Australian College of Physicians. His postdoctoral research at the Harvard School of Medicine and Massachusetts General Hospital with Dr. Larry Jameson focused on endocrine oncology. He completed his executive MBA at New York University’s Stern School of Business in 2011. Dr. Pestell has received numerous awards for his research discoveries including elected membership to ASCI (American Society of Clinical Investigation), Elected Member of the Royal Society of Medicine, Elected Fellow of the American Association for the Advancement of Science, the RD Wright Medallion, the Eric Susman Prize in Medicine, Advance Global Australian Award (Biotechnology), a Doctor of Medical Sciences, HonorisCausa, from the University of Melbourne and awards from Susan G. Komen (Light of Life award, Jamie Brooke Lieberman Award). Dr. Pestell received the Order of Australia (AO) in 2019 from Queen Elizabeth II and was elected as a Member of the Academia Europaea in 2024.
Since 2012
2 weeks ago
Ahhh, you got your feelings hurt, it’s ok, remember, no one has changed their mind because of you, not one single person, newbies, what, how many people are on this message board, so confused
Monroe1
2 weeks ago
Just wondering if those idiots are still down at the FDA who bad mouthed Nader and leronlimab? Bet some juicy stuff behind closed judges chamber door is going to oust those FDA miscreants. They may be gone already. At any rate, the cat's out of the bag and they will be gone... or will Bobby Jr. have to do it?
Time to buy IMO. More trials and other good news keeps happening since this turnaround began. The pps will catch up based on the merits of leronlimab with the team put together. In the scientific world sans the Covid lies, the mechanism of action of leronlimab is a buzz. Yep, the Bobby Jr. presence is already being felt as scientific editors and contributors are now being held accountable for nixing real science articles and promoting junk covid science. How gratifying to see liars and cheats get their due. I look for a huge surge in pps is the somewhat near future....even before Jan.20th. Know what you own. Leronlimab is a miracle discovery. In a health system devoid of scruples we suffered delay. Those days are ending fast. Pleasurable to know as CytoDyn advances while the working environment improves, leronlimab will have it's day.
Buying any dips worthy of my dollars.
$$$CYDY$$$ 2024 and onward. Great job Team.
"Fortunately, investment opportunities do not require actual blood to be spilled. Far less dramatic opportunities are pre¬sented every day. And the world’s greatest investors, in fact “The World’s Greatest Investor,” regularly employs market timing.
https://www.freemoneyfinance.com/2012/04/buy-when-theres-blood-in-the-street-and-why-buffett-is-a-market-timer.html